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As climate change alters environmental conditions, the incidence and global patterns of
human diseases are changing. These modifications to disease profiles and the effects upon
human pharmaceutical usage are discussed. Climate-related environmental changes are asso-
ciated with a rise in the incidence of chronic diseases already prevalent in the Northern
Hemisphere, for example, cardiovascular disease and mental illness, leading to greater use
of associated heavily used Western medications. Sufferers of respiratory diseases may exhibit
exacerbated symptoms due to altered environmental conditions (e.g., pollen). Respiratory,
water-borne, and food-borne toxicants and infections, including those that are vector borne,
may become more common in Western countries, central and eastern Asia, and across North
America. As new disease threats emerge, substantially higher pharmaceutical use appears
inevitable, especially of pharmaceuticals not commonly employed at present (e.g., antipro-
tozoals). The use of medications for the treatment of general symptoms (e.g., analgesics)
will also rise. These developments need to be viewed in the context of other major envi-
ronmental changes (e.g., industrial chemical pollution, biodiversity loss, reduced water and
food security) as well as marked shifts in human demographics, including aging of the pop-
ulation. To identify, prevent, mitigate, and adapt to potential threats, one needs to be aware
of the major factors underlying changes in the use of pharmaceuticals and their subsequent
release, deliberately or unintentionally, into the environment. This review explores the likely
consequences of climate change upon the use of medical pharmaceuticals in the Northern
Hemisphere.
CLIMATE CHANGE, DISEASE, AND
HEALTH
Anthropogenic releases of greenhouse
gases, such as carbon dioxide (CO2), methane
(CH4), and the nitrous oxides (NOx), have
played a significant role in the rise in global
temperatures since the mid-20th century, with
a mean surface temperature increase of 0.74◦C
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between 1906 and 2005 (Intergovernmental
Panel on Climate Change 2007). Projections
of future greenhouse gas emissions indicate
that atmospheric CO2 concentrations will
reach 500 to 1100 ppm by 2100, resulting in
mean surface warming of 1.1 to 6.4◦C by the
end of the 21st century (Intergovernmental
Panel on Climate Change 2007). Such major
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changes in the earth’s climate, and in the global
environment more generally, have enormous
significance for the human population (World
Health Organization 2009). Indeed, in 2009,
the Lancet Commission concluded that “cli-
mate change is the biggest global health threat
in the 21st century” (Editorial 2009).
Climate models predict more rain in high
latitudes leading to flooding, more forceful
tropical cyclones with greater wind speeds,
and a poleward shift in storm tracks. These
changes alter wind, precipitation, and tem-
perature patterns (Intergovernmental Panel on
Climate Change 2007; 2012). Several influen-
tial papers discussed the effects that climate
change might exert on pathogens (Mills et al.
2010; Relman et al. 2008), disease vectors
(Bengis et al. 2004; Bohm et al. 2007), environ-
mental health (Harvell et al. 2002; Campbell
et al. 2011; Epstein 2001a), livestock (Boxall
et al. 2009), human health (McMichael et al.
2006; Haines and Patz 2004; Cooney 2011;
Kang 2011), disease mitigation and control
strategies across various parts of the globe
or regarding specific health threats (Beggs
2010; Chitsulo et al. 2000; Costello et al.
2011), and even environmental contamination
by persistent organic pollutants (POPs; United
Nations Environmental Programme and Arctic
Monitoring and Assessment Programme 2010).
However, it is striking that little attention has
been paid to the influence that climate-related
changes in disease patterns and incidence may
exert upon medical pharmaceutical usage, both
in terms of their economics implications and
regarding their environmental impacts.
This review aims to provide a number
of illustrative examples to stimulate further
thought and debate, as opposed to conducting
a full systematic review of the subject; there-
fore, the applied methodology consists of uti-
lizing reviews of the impacts of climate change
upon disease distribution to first establish the
main areas for discussion. Selection of illus-
trative examples within the identified topics
was based upon the availability of information,
with respect to detailed predictions regarding
potential range shifts of agents (and vectors
and hosts, where applicable) and the presence
of several studies with similar or related find-
ings (as opposed to a single study in isolation,
thus with a limited data set). Further informa-
tion regarding pharmaceutical use was obtained
by searching a number of medical literature




The transport, fate, and subsequent eco-
toxicological effects of pharmaceuticals and
their metabolites in the environment have been
under examination for several decades and
have been extensively documented (Ayscough
et al. 2000; Halling-Sorensen et al. 1998;
Heberer 2002; Ternes 1998; Daughton and
Ternes 1999). As pharmaceuticals are neither
completely removed by routine sewage treat-
ment processes nor entirely degraded, their
ubiquitous presence in the environment is per-
haps unsurprising (Carballa et al. 2004; Golet
et al. 2002; Heberer et al. 2001; Kümmerer
2010). Concern is growing, however, about the
damaging consequences that these compounds
currently exert on biota, or may in the future.
This has been illustrated already by the deaths
of millions of vultures on the Indian subcon-
tinent following exposure to the nonsteroidal
anti-inflammatory drug (NSAID) diclofenac, the
well-known (and ongoing) cases of fish femi-
nization associated with excreted components
of women’s contraceptive pills, and the global
spread of antibiotic resistance in the environ-
ment (Taggart et al. 2007; Gilbert 2011; Hirsch
et al. 1999). The latter recently led the UK’s
Chief Medical Officer to declare, “Antibiotics
are losing their effectiveness at a rate that
is both alarming and irreversible—similar to
global warming” (Dame Sally Davis November
2012).
Changes in pharmaceutical use in the
Northern Hemisphere because of climate
change and the subsequent increased pres-
ence of drugs in the environment could have
unintended and unexpected effects on the
structure and functions of ecosystems. Impacts
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may be exacerbated by several factors, includ-
ing our growing global population, the aging
demographics of manyWestern and developing
nations, obesity, the depression epidemic,
and the rising availability of inexpensive
generic drugs. These factors may result in
elevated drug consumption and environmen-
tal release (Depledge 2011a; 2011b). Horizon
scanning will be necessary to assess which
pharmaceuticals could do most harm and iden-
tify potential mitigatory and preventative inter-
ventions.
The aim here is not to provide an exhaus-
tive review of changes in disease distribu-
tion and related pharmaceutical use due to
the complex and interactive nature of cli-
mate change and other factors affecting phar-
maceutical demand (including public health
mitigation and control measures, and socio-
economic status). Instead, this review highlights
specific climate change impacts that lead to
disease: for example, those linked to temper-
ature extremes, altered air quality, increased
rainfall, and flooding. This review illustrates
that changes in acute and chronic disease pat-
terns (communicable and non-communicable
diseases, vector, soil-, water- and food-borne
diseases) are inevitable, and that associated
changes in pharmaceutical use need to be
managed.
The three linked diagrams presented in
this review show how different pharmaceuticals
are associated with various health conditions.
Climate change could make these drugs more





Non-communicable diseases currently rep-
resent about two-thirds of all global diseases
(Friel et al. 2011). The number of people
affected will rise by several hundred thou-
sand worldwide as the climate continues to
change. The frequency, duration, and intensity
of heat waves will exert an especially strong
influence. An increasing number of vulnera-
ble people have suffered heat stress during
recent summers, causing thousands of deaths
across Europe. The elderly and those with
underlying cardiovascular and cerebrovascular
diseases face particular risks (D’Ippoliti et al.
2010). Treatment of cardiovascular disease is
often complex and involves a “cocktail” of
drugs tailored to the patient’s symptoms. This
often includes diuretics to reduce blood pres-
sure, statins to tackle high cholesterol, and
salicylates and antiplatelets to reduce blood clot
formation (Table 1). Prophylactic treatments for
those prone to cerebrovascular disease are simi-
lar to treatments used in cardiovascular disease,
although anticoagulants are most important
after an ischemic stroke (Table 1).
Personal behavior also alters during heat
waves: Individuals spend more time outdoors,
leading to more cases of sunburn and increased
use of cortisone (steroidal) creams and pain
relief medications (Table 1 and Figure 2). Longer
term exposure to sunlight may also produce
actinic keratoses of the skin. In severe cases,
or cases in which squamous-cell carcinoma
develops, treatment with chemotherapeutic
antimetabolites may be necessary (Table 1 and
Figure 2).
People tend to wash themselves and their
clothing more often in hotter weather, increas-
ing the use of deodorants and detergents
and other personal care products. Climate
change is also associated with more erratic
rainfall patterns, which in some regions results
in seasonal water shortages and less wash-
ing. Infections may occur if good stan-
dards of personal hygiene are not main-
tained. An infestation of the mite Sarcoptes
scabei produces dermatitis, and an infection
with the gram-negative bacteria Chlamydia tra-
chomatis produces conjunctivitis and trachoma
(World Health Organization 2001a; 2001b).
Antibiotics are necessary in the treatment of
trachoma (Table 1). Scabies infections are
dealt with using medicated creams that com-
monly contain insecticides, and even with oral
anthelmintics. Diseases that disrupt the skin sur-
face increase the risk of secondary bacterial
infection. In the case of scabies, the secondary
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FIGURE 1. Key to Link Diagrams (Figures 2–4) (color figure available online).
illness, impetigo may develop after infection
with Streptococcus or Staphylococcus (includ-
ing methicillin-resistant Staphyloccocus aureaus
[MRSA]). These diseases require additional drug
treatment, but often leave the patient vulnera-
ble to secondary infection, requiring additional
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FIGURE 2. Climatic Conditions causing non-communicable Illnesses and Associated Pharmaceutical Treatments (color figure available
online).
The term “global warming” is often used to
describe the impact of greenhouse gas accumu-
lation on the earth’s climate. However, it is now
clear that extreme climatic variations, involv-
ing both heating and cooling, take place. Heat
waves and more severe winters are likely in
the Northern Hemisphere. Overall winter tem-
peratures may be higher, but more frequent
and intense winter storms are predicted. Strong
storm winds increase cold exposure for many
vulnerable individuals, raising the incidence
of illnesses directly related to cold tempera-
tures (such as hypothermia and frostbite) and
lowering resistance to respiratory infection.
Complications are more likely to arise in those
with underlying cardiovascular and respiratory
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diseases (Conlon et al. 2011). Decongestants,
expectorants, pain relief medication, and, for
susceptible individuals, antiviral medications
are commonly used to treat common coughs,
colds, and influenza; these drugs may be
required in larger amounts in the future (Table 1
and Figure 2). Pneumonia and acute bronchi-
tis usually have a viral and/or bacterial etiology.
Because it can be difficult to ascertain the eti-
ology of these diseases, antibiotics are typically
administered, especially to those at greatest
risk (Table 1). The preceding examples illustrate
how more illness arising as the climate changes
may lead to increased pharmaceutical use.
Precipitation and Flooding
Climate change is affecting rainfall patterns
as well as temperature. The frequency and
intensity of flooding are increasing worldwide
(Lugeri et al. 2010; Kundzewicz et al. 2006;
2008). Health issues over a wide range are
associated with floods, but many depend upon
the socio-economic status of the population
affected and the responses of local authori-
ties. Extreme flood events, in particular flash
floods, elevate the risk of drowning, physical
injury such as broken bones, and hypothermia.
However, in areas where the local author-
ity response is inadequate, secondary conse-
quences may follow and exert a significant
influence on local pharmaceutical require-
ments. These include injury complications such
as infections, detrimental outcomes for mental
health, the emergence of communicable and
vector-borne diseases, particularly with con-
taminated water, and in the worst cases, mal-
nutrition (Du et al. 2010). Mental illnesses,
including psychological distress following nat-
ural disasters and severe environmental degra-
dation, are exacerbated by ill health and vice
versa (Verger et al. 2003; Chae et al. 2005;
Reacher et al. 2004; Speldewinde et al. 2009).
Various pharmaceuticals are needed to treat
the injuries and diseases linked with floods
(Tables 1 and 2 and Figure 2 and 3). To date,
however, detailed information about the extent
of increased drug use and associated costs has
not been assembled.
Climate and Air Quality
Climate change exacerbates the health
impacts of aeroallergens such as pollen and
mold spores, and increases the prevalence of
algal toxins. Changing meteorological condi-
tions and rising temperatures influence atmo-
spheric pollen content; this occurs through
changes in pollen production and shifts in,
or even lengthening of, the pollen-production
season. In addition, the geospatial distribu-
tion of pollen is changing: Plant ranges and
long-distance atmospheric transport are moving
poleward as new and predicted atmospheric
circulation patterns emerge. Interestingly, the
movement of plant ranges may also result in
the disappearance of some pollen types, along
with the emergence of other pollens more
suited to the new climate. The health con-
sequences of this have not been assessed.
Although agricultural crops grown on large
scales are one of the more important pollen
sources to consider, shifting plant ranges, crop
varieties, and densities make it difficult to pre-
dict whether pollen counts will rise overall.
Higher CO2 concentrations and temper-
atures associated with climate change may
result in the production of pollen that is more
allergenic in nature (defined as allergen con-
centration in the pollen grain) (Beggs 2010).
Conversely, increasing amounts of ground level
ozone globally may suppress photosynthesis
and ultimately pollen production (Royal Society
2008). Climate change is also expected to
affect the production of mold spores, particu-
larly indoors. This may be especially relevant in
developed countries, where adults and children
spend more than 90% of their time indoors
(U.S. Environmental Protection Agency Office
of Air and Radiation 1989).
In the future, coastal communities may
experience increased exposure to algal toxins in
aerosols (Anderson et al. 2012). In Florida, for
example, toxic algal blooms release aerosolized
brevetoxins into the atmosphere, exacerbating
asthma and other existing respiratory diseases
in exposed, susceptible individuals (Fleming
et al. 2011). Potential rises in the pharma-
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FIGURE 3. Vector-Borne Illnesses and Associated Pharmaceutical Treatments (color figure available online).
elevation in algal bloom events in marine
ecosystems that are being driven by climate
change (Intergovernmental Panel on Climate
Change 2007).
It is a compelling hypothesis that a rise in
aeroallergens and algal toxins influences rates
of respiratory disease, including asthma and
allergic rhinitis, while also exacerbating atopic
dermatitis. This leads to greater pharmaceu-
tical use. Prophylactic treatments for chronic
asthma consist of aerosolized medications of
beta-adrenergic agonists in combination with
corticosteroids and the leukotriene receptor
antagonists. For acute asthma attacks, beta-
agonists, anticholinergics, and corticosteroids
are used, while allergic rhinitis (“hay fever”)
is treated with corticosteroids, decongestants,
antihistamines, and leukotriene receptor antag-
onists. Antihistamines and corticosteroids are
used to treat atopic dermatitis (eczema), which
often occurs alongside asthma and in allergic
rhinitis sufferers (Table 1 and Figure 2).
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Respiratory conditions are made worse by
deteriorating air quality associated with cli-
mate change. Kinney (2008) describes how
more sunlight and higher temperatures lead
to increased ozone formation at ground level.
Further, long periods of drought elevate the risk
of wildfires, which intensify fine particulate air
pollution. This has been particularly apparent
in Australia in recent years (Chen et al. 2006).
Floods elevate the prevalence of molds and
microbes, which also aggravate respiratory ill-
nesses (Kunii et al. 2002; Biswas et al. 1999;
Centers for Disease Control and Prevention
2006; Riggs et al. 2008). All of these fac-
tors worsen symptoms in those with respiratory
conditions, and increase pharmaceutical use.
VECTOR-BORNE DISEASES
Changes in climate prompt changes in the
abundance and distribution of populations of
organisms in ecosystems. Since pathogens are
transmitted between a variety of vertebrate ani-
mals and humans, changes in the incidence of
vector-borne disease can be expected. These
zoonotic infections represent approximately
60% of human pathogenic illnesses (Bengis
et al. 2004). The impacts that climate change
exerts upon the pathogen itself, pathogen vec-
tors, and the hosts of vectors are important to
take into consideration.
Mosquito Vectors
Various models have predicted the spread
of mosquito species poleward in the Northern
Hemisphere. Fischer et al. (2011) modeled
the European distribution of the Asian tiger
mosquito, Aedes albopictus Skuse, under cli-
matic change using four different models. Areas
suitable for A. albopictus are already increas-
ing in Western and Central Europe, although
their spread into Eastern Europe is expected to
be delayed. Suitable areas in Southern Europe
are likely to fall in number, suggesting the
species range will shift. As a vector organism,
A. albopictus can transmit at least 22 types
of arboviruses (including all four dengue fever
serotypes, yellow fever, chikungunua virus,
West Nile virus, eastern equine encephalitis,
Usutu virus, and Ross River virus), as well
as the parasitic nematodes Dirofilaria immitis
and D. repens (Gratz 2004; Mitchell et al.
1987; Cancrini, et al. 2003a; 2003b; Calzolari
et al. 2010; Vázquez et al. 2011). Transmission
of the Dirofilaria spp. to humans rarely pro-
duces health problems, although occasion-
ally treatment with an antiparasitic agent and
an anthelmintic is required (Table 2 and
Figure 3).
Pharmaceuticals are also used in prophy-
lactically and treatment for pets succumbing to
Dirofilaria infections (Table 2). The spread of
A. albopictus in Europe and the United States
has already affected human health; endemic
chikungunya virus and dengue fever have reap-
peared in Italy, France, Croatia, Hawaii, Texas,
and Florida (Rezza et al. 2007; La Ruche et al.
2010; Queyriaux et al. 2008; Schmidt-Chanasit
et al. 2010; Gjenero-Margan et al. 2011;
Centers for Disease Control and Prevention
2010b; Adalja et al. 2012). The zoonotic fla-
vivirus West Nile virus is now also widespread
in the United States and Canada after its sus-
pected introduction by migratory birds in 1999
(Epstein 2001b; Rappole et al. 2000; El Adlouni
et al. 2007).
It is temperature that largely determines
the development of the protists Plasmodium
vivax and P. falciparum, which produce malaria.
Temperature changes due to climate change
may lead to a 12–27% increase in transmis-
sion (Martens et al. 1997), placing an additional
200 million individuals at risk of contract-
ing malaria (Béguin et al. 2011) and requir-
ing an enormous rise in drug therapy. Former
breeding sites for the malaria mosquito vec-
tors, Anopheles spp. and Aedes spp., are still
present in many developed countries, includ-
ing the United States and Southern and Central
Europe, where malaria may return (Martens
et al. 1997). However, since malaria was erad-
icated previously, it seems likely that manag-
ing this problem by land drainage and the
use of pesticides will be feasible if the need
arises. Further information about the range of
medications required to treat mosquito-borne
diseases are provided in Table 2 and Figure 3.
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Tick Vectors
Mosquitoes are not the only disease vectors
that are affected by climate change. The range
of the castor bean/sheep tick, Ixodes ricinus,
for example, is spreading northward (Lindgren
et al. 1999). Lyme disease and tick-borne
encephalitis are caused by several species of
Borrelia bacteria and the tick-borne encephali-
tis virus, respectively. Both will be of huge
concern for Europe (Gage et al. 2008). Lyme
disease is treated with antibiotics (Table 2 and
Figure 3). Although an inactivated vaccine is
available for tick-borne encephalitis, there is not
an established treatment program for sufferers
(see Table 2 for associated medications).
Modeling indicates a range shift for trans-
mission of the zoonotic bacterial pathogen
Francisella tularensis, which produces tularemia
(or “rabbit fever”; Nakazawa et al. 2007).
With diseases of this type, in which complex
pathogen–vector–host interactions occur, the
effects of climate change on the vectors (ticks,
fleas, and flies), their hosts (rodents and lago-
morphs), and the pathogen itself (which may be
directly transmitted between vertebrate hosts
and humans) needs to be considered (Harvell
et al. 2002; Relman et al. 2008). The F. tularen-
sis subspecies responsible for the infection,
strain virulence, and infection route play impor-
tant roles in the symptomatic profile observed,
although all cases are treated with antibiotics
(Table 2 and Figure 3).
Flea Vectors
The flea Xenopsylla cheopis is the vector
of the bacterial pathogen Yersinia pestis, which
produces plague in humans. Prevailing climate
is crucial in determining disease transmission,
with warmer and wetter conditions benefitting
both plague vectors and hosts. Once again, cli-
mate change is driving a poleward range shift
in transmission of the disease (Enscore et al.
2002; Eisen et al. 2007; Nakazawa et al. 2007;
Parmenter et al. 1999). The importance of
climate in relation to plague transmission was
further emphasized by studies exploring the
relationship between climatic events (e.g., the
Pacific decadal oscillation and El Niño southern
oscillations) and human transmission rates, and
with prairie dog colony extinction events (Ari
et al. 2008; Stapp et al. 2004). The infection
route for Y. pestis in humans determines which
form of disease is contracted (bubonic plague,
pneumonic plague, or septicemic plague), thus
influencing the symptomatic response. More
antibiotics will be used to treat plague cases—
drugs that are similar to those used in tularemia
(Table 2 and Figure 3). Where prophylactic
measures are needed to limit further spread
of the disease (e.g., when an individual has
had close contact with someone suffering from
pneumonic plague), antibiotics are also used.
Fly Vectors
Visceral and cutaneous leishmaniasis are
produced by different subspecies of the
protozoan Leishmania; both are now endemic
in Europe. The impact of climatic change on
the distribution of leishmaniasis vectors (i.e.,
the sandfly Phlebotomus and Lutzomyia spp.) is
difficult to predict, as the presence of specific
vegetative habitats correlates with transmission
rates. Localized land use will therefore exert a
significant impact (Ready 2010). However, in
areas where leishmaniasis is endemic, climatic
events such as El Niño southern oscillations may
result in greater transmission rates in subse-
quent years (Franke et al. 2002). El Niño events
are expected to increase in frequency as cli-
mate change proceeds, leading to an elevated
worldwide risk of infection with Leishmania.
The presence and density of hosts (includ-
ing canines, marsupials, and rodents), which
serve as disease reservoirs (Diniz et al. 2008),
is likely to be of even greater importance
to leishmaniasis transmission. These factors
affect disease incidence and need for drug
treatment. The general health of individu-
als is also significant, including co-infections
of leishmaniasis with HIV, which is well
known in Southern Europe (Alvar et al. 1997;
Rosenthal et al. 1995). Pentavalent antimony
compound medications are used in preventa-
tive and treatment regimes, along with a num-
ber of antimicrobial/antifungal/antiprotozoal
drugs (Table 2 and Figure 3). Supportive therapy
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is also required to tackle co-occurring anemia,
hemorrhagic complications, secondary infec-
tions, and the nutritional status of the infected
individual.
Other Vectors
Chagas disease (also known as American try-
panosomiasis) is another vector-borne disease
that may become increasingly important as cli-
mate change progresses. The pathogen respon-
sible is the flagellate protozoan Trypanosoma
cruzi, with Triatominae (assassin bugs) as the dis-
ease vector. Chagas disease starts with an acute
infection, which, over years, develops into a
chronic condition affecting the heart, digestive,
and nervous systems. Antiparasitic drug use will
increase if climate change enables the incidence
of Chagas disease to rise. In turn, the application
of treatments for cardiac, digestive, and neuro-
logical symptoms will also rise (Bern et al. 2007;
Table 2 and Figure 3).
Wild and domesticated mammals are
among the wide range of mammalian hosts car-
rying the disease’s insect vector. Significant cor-
relations between populations of Triatominae
vectors and host rodents have been found
(Peterson et al. 2002). The influence of cli-
mate change on the insect vector is difficult to
predict, but the geographic distribution of wild
vectors will probably widen due to higher tem-
peratures (Carcavallo 1999). Lower humidity
might also shorten life cycles.
Hosts and Disease Reservoirs
The prevalence of various vector-borne ill-
nesses heavily depends on how climate change
impacts host ranges and densities. Climate
change might reduce disease transmission as
species are driven out of areas that become too
wet or unstable to support them. Nonetheless,
range extensions have attracted most attention.
For example, rodent populations are affected
by precipitation: Heavy rainfall events that
increase primary production subsequently
result in a boom in rodent populations (Brown
and Singleton 1999; Leirs et al. 1996; Lima
et al. 1999; Brown and Zeng 1989). When
drought precedes these rainfall events, rodent
outbreaks are magnified by declining predator
populations (Epstein 2001a). Regardless of
population size, extreme climatic events raise
the likelihood of disease transmission as rodent
behavior is modified (e.g., entering human
dwellings to seek food or refuge) (Gubler et al.
2001).
In more rural areas worldwide, the effects of
climatic change on wild animals serving as dis-
ease reservoirs and vector hosts may be one of
the most important factors influencing vector-
borne diseases for humans and livestock. Bohm
et al. (2007) illustrated the key role of wild
vertebrates by studying the expanding range
of all six UK deer species. Wild animals are
not vaccinated so may act as a disease reser-
voir, transferring diseases to livestock, humans,
or invertebrate vectors. Wild deer are com-
monly subject to at least 39 infestations, most of
which are produced by contact with livestock.
Regions where deer populations are extending
their range or becoming denser, due to chang-
ing climatic conditions, may see a rise in tick-
and flea-borne diseases.
The drugs required to treat zoonotic and
vector-borne diseases originate from diverse
classes within the pharmaceutical arsenal. The
changing ranges of these types of diseases could
lead to major shifts in drug use profiles (Table 2
and Figure 3). It may become necessary to treat
more livestock, either as a control measure or
to address infection. People spending time in
natural areas through occupation or recreation
will be at greater risk. Those living in “animal-
loving” countries may also be more vulnerable
to vector-borne and zoonotic diseases because
pets can be vector hosts or reservoirs of dis-
ease. Further application of pharmaceuticals
and insecticides on pets, either for treatment
or as a prophylactic measure, may be required
(Otranto and Wall 2008).
SOIL-, WATER-, AND FOOD-BORNE
DISEASES
The World Health Organization and the
United Nations Environment Programme are
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among those drawing attention to the threat cli-
mate change poses to soil and water quality,
and food security. These changes have major
implications for human health and pharma-
ceutical use. Outbreaks of food poisoning for
example are expected rise by 10,000 cases per
year in the United Kingdom as climate change
proceeds.
Soil-Borne Pathogens
Human cryptococcal infections produce
cryptococcal meningitis or pneumonia. The
inhalation of fungal spores also leads to simul-
taneous cryptococcomas in the lung, brain,
or muscle. These infections are primarily pro-
duced by the yeast species Cryptococcus neo-
formans and C. gattii, and historically have been
seen in tropical and subtropical zones (Sorrell
2001). The last decade has seen escalating
outbreaks of C. gatti in human and animal pop-
ulations in Canada and the United States, some
of which were severe enough to result in death
(Datta et al. 2009; Centers for Disease Control
and Prevention 2010a; MacDougall et al. 2007;
Galanis and MacDougall 2010). Cryptococcus
gatti emergence in temperate regions has been
attributed to the creation of conditions suit-
able for spore survival and propagation because
of climate change, or to the adaptation of C.
gatti to a new climatic niche. Cryptococcus
gatti is expected to spread to the Northern
Hemisphere over the coming years (Dixit et al.
2009; Datta et al. 2009). Cryptococcal infec-
tions are treated with antifungal agents, and
corticosteroids when the central nervous system




It is known that climate change is likely
to produce more floods and heavy rain due
to warming of the oceans (Haines and Patz
2004; Diaz 2004). Indirect health conse-
quences include a surge in freshwater diar-
rheal diseases, such as cryptosporidiosis and
cholera, which are correlated to sewer over-
flows, wastewater treatment plant overflows,
and contamination of water supplies by storm
water runoff (O’Shea and Field 1992; Lipp et al.
2001a; 2001b; 2002; Rose et al. 2001; 2002;
Checkley et al. 2000; Colwell 1996; Pascual
et al. 2000; Portier et al. 2010). The trans-
mission of pathogens such as E. coli, Shigella,
Salmonella, and viral hepatitis A is also likely
to increase as a result of water contamination.
The transmission dynamics of these diseases are
further complicated if livestock or crops are
contaminated with feces, posing a health risk
to farm and outdoor workers (Casteel et al.
2006; Tanabe et al. 1999; Pianetti et al. 2004).
In severe cases, or situations in which there
is a high risk of human-to-human transmis-
sion, the use of antibiotics is required. Where
complications occur, such as the development
of hemolytic uremic syndrome or postinfec-
tious arthritis, a number of supportive medical
therapies are needed (Table 3 and Figure 4).
Schistosomiasis, also known as bilharzia,
is a zoonotic disease produced by dige-
netic trematode flatworms (genus Schistosoma).
Three species are responsible for most human
infections including cases observed in Northern
Hemisphere endemic countries (Turkey and
areas of the eastern Mediterranean) (Gryseels
et al. 2006; Chitsulo et al. 2000). Human
infection occurs when host freshwater snails
release free-swimming larval parasites (cer-
caria) into the water. These parasites burrow
into human skin upon contact. Infestations
develop from acute cases (Katayama fever)
into chronic schistosomiasis with varying lev-
els of severity, and lead to life-threatening
hepatosplenic disease and associated hepatic,
periportal, and portal complications (Pearce
and MacDonald 2002). The anthelmintic
Praziquantel is effective against all Schistosoma
species, and is often administered in conjunc-
tion with corticosteroids to suppress hypersen-
sitivity (Gryseels et al. 2006); see Table 3 and
Figure 4.
The influences of climate change on the
zoonotic helminthiase (parasitic worm) diseases
have not received as much attention as on
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FIGURE 4. Soil, Water and Food-Borne Illnesses and Associated Pharmaceutical Treatments (color figure available online).
pathogens. The effects on helminthiases and
the other zoonotic pathogens differ because
of the substantially longer life cycles of the
helminths. It subsequently takes longer for
organismal responses to changing environmen-
tal conditions to become apparent (Mas-Coma
et al. 2009). As snails are essential to the life
cycle of Schistosoma, the presence of appropri-
ate snail species in the Northern Hemisphere
is a key determinant in the emergence of this
disease. Recent range expansions of 4 of the
34 known Biomphalaria species into areas such
as Egypt, Hong Kong, and southern states of
the United States have been observed (Pointier
et al. 2005). The presence of B. tenagophila
within Eastern Europe (Romania) has also been
confirmed (Majoros et al. 2008). This study did
not detect the presence of trematode larvae
inside these snails, but the presence of estab-
lished snail populations means schistosomiasis
could be introduced, and become endemic, via
tourist or immigrant feces contaminated with
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flukes or eggs (Majoros et al. 2008). An inves-
tigation in Brazil suggested that the duration
of drought periods and snail population den-
sity were vital determinants for schistomiasis
prevalence, and that coastal regions were at
greatest risk (Bavia et al. 1999).
Despite extensive control programs,
schistomiasis is common in China, leading
researchers such as Zhou et al. (2008) to
investigate the impact of climate change
upon transmission rates via risk mapping.
Schistosomiasis ranges are expanding into
the northern (currently) nonendemic regions,
placing a total of 8.1% of China’s surface area
at risk by 2050. The recent range expansion of
the snail, and the impact of drought and rising
temperatures upon schistosomiasis transmis-
sion, imply that climatic change will increase
bilharzia prevalence and the associated use of
pharmaceuticals (Gajadhar and Allen 2004).
Other trematodes (such as the liver and lung
parasites Fasciola, Clonorchis, Opisthorchis,
and Paragonimus) are also likely to be affected
by climate change in a manner similar to
effects on Schistosoma, through the effects
on their Biomphalaria hosts (Morgan et al.
2001). Infections by these liver and lung flukes
are typically treated with anthelmintics and
corticosteroids when there is a risk of damage




The study of Vibrio spp. provides an insight
into the influence of climatic change upon
estuarine and marine-borne illnesses because
of its effects on ecology and pathogen abun-
dance. As Vibrio spp. have a symbiotic rela-
tionship with plankton (some of which are
associated with harmful algal blooms), modifi-
cations to plankton or other host populations
affect Vibrio spp. abundance. Vibrio vulnifi-
cus infects humans during recreational and
occupational activities (such as fishing and
swimming) when open wounds are present,
while V. parahaemolyticus is spreading its range
with rising temperatures and is responsible for
an increasing number of infections occurring
when contaminated shellfish are eaten (Lipp
and Rose 1997; Wittman and Flick 1995).
Gastrointestinal illnesses produced by Vibrio
infections are usually treated with rehydration
salts. However, if infection of the bloodstream
occurs and/or there is underlying liver disease
and immunosuppression, life-threatening sep-
ticemia arises and use of antibiotics is required
(Table 3 and Figure 4).
Vibrio cholera, the best known of the Vibrio
spp., is associated with zooplankton and also
found in the marine system. Phytoplankton is
the primary food source of zooplankton, and
when phytoplankton bloom in warmer peri-
ods, V. cholera populations also increase (Lobitz
et al. 2000; Barbieri et al. 1999). Warmer water
temperatures associated with climate change
are expected to expand the prevalence and
range of V. cholera on both geospatial and
temporal scales. This is because of ecological
impacts upon phytoplankton, intrusion of salt
water into inland systems due to sea-level rise,
and the increasing frequency of El Niño south-
ern oscillation events (Colwell and Huq 1998;
Colwell 1996; Lipp et al. 2002). With rising V.
cholera populations, the risk of cholera cases
in humans increases due to the consumption
of raw or undercooked contaminated shell-
fish, which produce diarrhea and septicemia
(Hlady and Klontz 1996). This inevitably results
in a rise in the use of antibiotics and other
pharmaceuticals. It is worth pointing out, how-
ever, that factors other than climate change
may be more significant in increasing cholera
outbreaks: Evidence suggests that other anthro-
pogenic factors (e.g., declining medical infras-
tructure, persistent insanitary conditions, and
unintentional transmission of cholera via aid
workers) are much more likely to foster increas-
ing numbers of cholera outbreaks.
AGRI-/AQUACULTURE
Boxall et al. (2009) highlighted how chang-
ing climatic conditions might increase the
level of contact between farm workers and
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livestock. If grazing land is waterlogged or ani-
mals suffer heat stress, it may be necessary to
house livestock indoors. This elevates human-
to-animal contact and the necessity for farm
workers to dispose of manure. In turn, the
risk of transmitting zoonotic pathogens such
as Cryptosporidium rises (Reif et al. 1989;
Boxall et al. 2009). Altered weather condi-
tions driven by climate change may impair
the health of livestock and increase the sus-
ceptibility of animals to infection. In the
aquaculture sector, similar environmental con-
ditions enable new diseases, pests, and par-
asites to emerge, producing changes in bio-
diversity, and temperature-related physiolog-
ical stresses. These changes ultimately bring
about range shifts and potential extinctions
and/or mass mortalities of certain populations
(Cochrane et al. 2009; Harvell et al. 1999;
Hofmann et al. 2001; Occhipinti-Ambrogi
2007; Barange and Perry 2009; Rahel and
Olden 2008; United Nations Environmental
Programme 2009). To maintain meat and
fish production under difficult and variable
climatic conditions, the usage of veterinary
pharmaceuticals (such as growth hormones,
antifungal or antiparasitic agents, and antibi-
otics) will rise.
This important issue cannot be consid-
ered in detail here, but it is clear that cli-
mate change is more generally affecting prac-
tices in agriculture and aquaculture, leading
to increased use of veterinary pharmaceuticals.
This has major implications for human health.
For example, the extensive employment of
antibiotics within veterinary contexts is exert-
ing significant adverse consequences for drug
efficacy. The rising resistance of Salmonella to
fluroquinolone antibiotics is an example. This
resistance occurred only when fluroquinolones
became licensed for veterinary use. For more
extensive discussion regarding antimicrobial
resistance, see available reviews in the literature
(Taylor et al. 2011; Wright 2010; Kümmerer
2009a; 2009b).
Climate change will enable new weeds,
pests, and diseases to thrive and will allow
indigenous pests to proliferate. This poses chal-
lenges for arable crop production and is likely
to result in higher pesticide use (Reidsma et al.
2007; Baker et al. 2000; Bale et al. 2002;
Olesen et al. 2011). There is already evi-
dence that warmer temperatures are leading
to outbreaks of infestation, and a poleward
spread of pests such as the European corn borer
(Ostrinia nubilalis, Hubner) (Trnka et al. 2007).
Exposure to numerous biocides was shown to
harm human health. Epidemiological studies
associated the incidence of Parkinson’s dis-
ease with pesticide exposure (Ascherio et al.
2006). Repeated exposure to low doses of
organophosphate biocides is thought to play
an important role in neurotoxicity and devel-
opment of cancers such as leukemia and lym-
phoma (López et al. 2007; Alavanja et al.
2004). Chlorphenoxy herbicide exposure has
been linked with a range of human health
impacts, including congenital, urogenital, and
muscuolskeletal abnormalities, malformation of
respiratory and circulatory systems, and possi-
bly cancer (Stillerman et al. 2008).
Treatment of these serious and often debili-
tating diseases requires long-term employment
of polypharmacy (including psychoactive
drugs, dopamine agonists, monoamine oxidase
inhibitors, and catechol O-methyltransferase
inhibitors for Parkinson’s disease). For the treat-
ment of cancers such as leukemia, induction
chemotherapy is required, which typically
involves the employment of corticosteroids,
mitotic inhibitors, and anthracycline drugs,
followed by consolidation therapy with
antimetabolite drugs. In short, the increasing
use of pharmaceuticals and other chemicals
in agri-/aquaculture due to climate change
is leading to environmental contamination
and a range of acute and chronic diseases
in humans and other animals. Ironically,
this is necessitating an even greater use of
pharmaceuticals.
CONCLUDING REMARKS
Over the next few decades, climate change
in the Northern Hemisphere is likely to exacer-
bate diseases, some of which are already com-
mon, especially non-communicable diseases
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(e.g., cardiovascular disease and mental ill-
ness). Evidence is presented here that these
changes will be associated with altered pat-
terns of pharmaceutical use, notably the
use of medications now classified as “heavy
usage Western drugs” (e.g., beta-blockers,
ACE inhibitors, statins, salicylates, antiplatelets,
vasodilators, anticoagulants, and a myriad of
antidepressants, antipsychotics, and sedatives;
Figure 2). As the weather changes, those suf-
fering from respiratory diseases such as asthma
and allergic rhinitis may, in many locations,
experience more severe symptoms. An increase
in the number of sensitive individuals also
seems plausible. The incidence of infectious
disease is likely to rise (e.g., cryptococcal
infection), and substantial growth in human
and animal diarrheal disease is predicted as
the transmission of Cryptosporidium, Vibrio
spp., Escherichia coli, Salmonella, and other
pathogens is promoted. Bacterial infections
in general are likely to proliferate with the
changing climate, including both primary (e.g.,
scabies, conjunctivitis) and secondary (e.g.,
impetigo, Staphylococcus, Streptococcus) infec-
tions (see Figure 2).
The emergence of parasitic and infectious
diseases, some of which are already proliferat-
ing, will accelerate the use of drugs now used
only irregularly in the Northern Hemisphere.
These pharmaceuticals will undoubtedly gain
entry into the environment but have to date
received little attention from environmental
researchers and ecotoxicologists. Vector-borne
diseases that are likely to occur more widely as
the climate changes include insect-borne and
tick-borne infections. Among the new parasites
now being seen more often are liver and lung
helminths, including Schistosoma spp. To treat
these emerging illnesses, medications for para-
sitic diseases (e.g., insecticides, anthelminitics,
antimalarials, antimonials, antiprotozoals) and
the symptomatic treatment of encephalitis and
cryptoccocal meningitis (e.g., anticonvulsants,
antipyretics, antiemetics) will be required in
ever larger volumes (Figure 3 and 4). In addi-
tion, the increased use of pharmaceuticals used
to treat common symptoms, or to prevent fur-
ther risks to health, can be expected (e.g.,
analgesics, anti-inflammatory, and antibacterial
or antifungal agents) (Figure 2 to 4).
The potential impact of climate change
on disease incidence in the future remains
uncertain and is subject to controversy, with
opposing views represented in the scientific lit-
erature. Recent demands for greater rigor and
a deeper appreciation of the complexity of
climate change and disease interactions merit
urgent consideration (Lafferty 2009; Rohr et al.
2008; Hay et al. 2002). A balanced assess-
ment of available literature does, however,
suggest that climate change has the poten-
tial to influence human health and diseases
on a global scale, as shifts in climatic zones
occur. Certain diseases, such as those discussed
herein, have the potential to increase in inci-
dence in a number of regions. There is also
likely to be a concurrent decrease in the inci-
dence of other diseases due to climate change;
however, available literature does not generally
focus upon decreased morbidity due to climate
change. Such studies would be particularly ben-
eficial when considering future provision of
medical/health resources. The reality is that sci-
entists are currently unable to predict with a
high level of certainty when and where specific
changes will occur.
It is known that geospatial disease distribu-
tions are being (and will be further) modified
by changing climatic conditions. As a result,
pharmaceutical use will alter, together with
the release of these drugs into the environ-
ment. Whether new diseases will emerge in
specific regions, become endemic, or pose a
significant risk to human health will depend
largely on local control and mitigation strate-
gies, including vector control programs (World
Health Organization 2010). This in turn will
depend on local policies (Stern 2006). A num-
ber of other factors, such as regional poverty,
human migration, land use, water quality, air
quality, and ecological adaptation, will play
fundamental roles in determining the prolifer-
ation of diseases. Due to uncertainty on the
impact of climate change (in isolation) upon dis-
ease distribution, it is not possible to accurately
discuss the influence of other factors without
significant speculation, particularly as these are
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likely to be highly geographically localized and
consist of complex networks of influencing fac-
tors, thereby complicating current predictions
of future risks to human health.
With different disease profiles, the localized
requirements for pharmaceuticals will alter in
both quantity and type, regardless of whether
control or mitigation strategies are put in place.
This is because pharmaceuticals might act as the
foundation of these programs, especially where
a strategic prophylactic approach is being taken
(Costello et al. 2011). Scientists investigating the
environmental transport, fate, and ecotoxicol-
ogy of drugs in ecosystems need to be prepared
to reassess which pharmaceuticals are targeted
for investigation.
The information presented here highlights
some of the types of drugs that are likely
to be used more extensively in the Northern
Hemisphere. Further investigations addressing
the interactions between pharmaceuticals and
climate change are urgently needed to quan-
tify pharmaceutical use, determine the eco-
nomic implications (both in terms of drug pro-
vision and environmental consequences), and
explore the medical and veterinary implications
(in terms of training, prevention, and treat-
ment). Research is also needed to develop
a more systematic approach to future global
disease management in a rapidly changing
world.
REFERENCES
Adalja, A. A., T. K. Sell, N. Bouri, and C. Franco.
2012. Lessons learned during dengue out-
breaks in the United States, 2001–2011.
Emerg. Infect. Dis. 18: 608–614.
Alavanja, M. C. R., J. A. Hoppin, and F. Kamel.
2004. Health effects of chronic pesticide
exposure: Cancer and neurotoxicity. Annu.
Rev. Public Health 25: 155–197.
Alvar, J., C. Cañavate, B. Gutiérrez-Solar,
M. Jiménez, F. Laguna, R. López-Vélez, R.
Molina, and J. J. Moreno. 1997. Leishmania
and human immunodeficiency virus coin-
fection: The first 10 years. Clin. Microbiol.
Rev. 10: 298–319.
Anderson, D. M., A. D. Cembella, and G. M.
Hallegraeff. 2012. Progress in understanding
harmful algal blooms: Paradigm shifts and
new technologies for research, monitoring,
and management. Annu. Rev. Mar. Sci. 4:
143–176.
Ari, T. B., A. Gershunov, K. L. Gage, T. Snäll, P.
Ettestad, K. L. Kausrud, and N. C. Stenseth.
2008. Human plague in the USA: The
importance of regional and local climate.
Biol. Lett. 4: 737–740.
Ascherio, A., H. Chen, M. G. Weisskopf, E.
O’Reilly, M. L. McCullough, E. E. Calle, M.
A. Schwarzschild, and M. J. Thun. 2006.
Pesticide exposure and risk for Parkinson’s
disease. Ann. Neurol. 60 :197–203.
Ayscough, N. J., J. Fawell, G. Franklin,
and W. Young. 2000. Review of human
pharmaceuticals in the environment. R & D
Technical Report P390. UK Environmental
Agency, Bristol.
Baker, R. H. A., C. E. Sansford, C. H. Jarvis,
R. J. C. Cannon, A. MacLeod, and K. F. A.
Walters. 2000. The role of climatic mapping
in predicting the potential geographical
distribution of non-indigenous pests under
current and future climates. Agric. Ecosyst.
Environ. 82: 57–71.
Bale, J. S., G. J. Masters, I. D. Hodkinson, C.
Awmack, T. M. Bezemer, V. K. Brown, J.
Butterfield, A. Buse, J. C. Coulson, J. Farrar,
J. E. G. Good, R. Harrington, S. Hartley,
T. H. Jones, R. L. Lindroth, M. C. Press, I.
Symrnioudis, A. D. Watt, and J. B. Whittaker.
2002. Herbivory in global climate change
research: Direct effects of rising temperature
on insect herbivores. Global Change Biol. 8:
1–16.
Barange, M., and R. I. Perry. 2009. Physical
and ecological impacts of climate change rel-
evant to marine and inland capture fisheries
and aquaculture. In Climate change implica-
tions for fisheries and aquaculture: overview
of current scientific knowledge, FAO
Fisheries and Aquaculture technical paper
no. 530, ed. K. Cochrane, C. De Young,
D. Soto, and T. Bahri. Rome, Italy: Food
and Agriculture Organization of the United
Nations.
PHARMACEUTICAL USE AND CLIMATE CHANGE 313
Barbieri, E., L. Falzano, C. Fiorentini, A.
Pianetti, W. Baffone, A. Fabbri, P. Matarrese,
A. Casiere, M. Katouli, I. Kuhn, R. Mollby,
F. Bruscolini, and G. Donelli. 1999.
Occurrence, diversity, and pathogenicity
of halophilic Vibrio spp. and non-O1
Vibrio cholerae from estuarine waters along
the Italian Adriatic coast. Appl. Environ.
Microbiol. 65: 2748–2753.
Bavia, M. E., L. F. Hale, J. B. Malone, D. H.
Braud, and S. M. Shane. 1999. Geographic
information systems and the environmental
risk of schistosomiasis in Bahia, Brazil. Am. J.
Trop. Med. Hyg. 60: 566–572.
Beggs, P. J. 2010. Adaptation to impacts of
climate change on aeroallergens and allergic
respiratory diseases. Int. J. Environ. Res.
Public Health 7: 3006–3021.
Béguin, A., S. Hales, J. Rocklöv, C. Åström,
V. R. Louis, and R. Sauerborn. 2011. The
opposing effects of climate change and
socio-economic development on the global
distribution of malaria. Global Environ.
Change. 21: 1209–1214.
Bengis, R. G., F. A. Leighton, J. R. Fischer, M.
Artois, T. Morner, and C. M. Tate. 2004.
The role of wildlife in emerging and re-
emerging zoonoses. Rev. Sci. Technol. Oie.
23: 497–511.
Bern, C., S. P. Montgomery, B. L. Herwaldt,
A. Rassi, J. A. Marin-Neto, R. O. Dantas,
J. H. Maguire, H. Acquatella, C. Morillo,
L. V. Kirchhoff, R. H. Gilman, P. A. Reyes,
R. Salvatella, and A. C. Moore. 2007.
Evaluation and treatment of Chagas disease
in the United States. J. Am. Med. Assoc. 298:
2171–2181.
Biswas, R., D. Pal, and S.P. Mukhopadhyay.
1999. A community based study on health
impact of flood in a vulnerable district of
West Bengal. Indian J. Public Health 43:
89–90.
Bohm, M., P. C. L. White, J. Chambers, L.
Smith, and M. R. Hutchings. 2007. Wild
deer as a source of infection for live-
stock and humans in the UK. Vet. J. 174:
260–276.
Boxall, A. B. A., A. Hardy, S. Beulke, T.
Boucard, L. Burgin, P. D. Falloon, P. M.
Haygarth, T. Hutchinson, R. S. Kovats, G.
Leonardi, L. S. Levy, G. Nichols, S. A.
Parsons, L. Potts, D. Stone, E. Topp, D. B.
Turley, K. Walsh, E. M. H. Wellington, and R.
J. Williams. 2009. Impacts of climate change
on indirect human exposure to pathogens
and chemicals from agriculture. Environ.
Health Perspect. 117: 508–514.
Brown, J. H., and Z. Zeng. 1989. Comparative
population ecology of eleven species of
rodents in the Chihuahuan Desert. Ecology
70: 1507–1525.
Brown, P. R., and G. R. Singleton. 1999. Rate
of increase as a function of rainfall for house
mouse Mus domesticus populations in a
cereal-growing region in southern Australia.
J. Appl. Ecol. 36: 484–493.
Calzolari, M., P. Bonilauri, R. Bellini, A. Albieri,
F. Defilippo, G. Maioli, G. Galletti, A. Gelati,
I. Barbieri, M. Tamba, D. Lelli, E. Carra, P.
Cordioli, P. Angelini, and M. Dottori. 2010.
Evidence of simultaneous circulation of
West Nile and Usutu viruses in mosquitoes
sampled in Emilia-Romagna region (Italy) in
2009. PLoS One 5: e14324.
Campbell, A. H., T. Harder, S. Nielsen, S.
Kjelleberg, and P. D. Steinberg. 2011.
Climate change and disease: bleaching of
a chemically defended seaweed. Global
Change Biol. 17: 2958–2970.
Cancrini, G., A. Frangipane di Regalbono,
I. Ricci, C. Tessarin, S. Gabrielli, and M.
Pietrobelli. 2003a. Aedes albopictus is a
natural vector of Dirofilaria immitis in Italy.
Vet. Parasitol. 118: 195–202.
Cancrini, G., R. Romi, S. Gabrielli, L. Toma,
M. Di Paolo, and P. Scaramozzino. 2003b.
First findings of Dirofilaria repens in natural
populations of Aedes albopictus. Med. Vet.
Entomol. 17: 448–451.
Carballa, M., F. Omil, M. J Lema, M.
Llompart, C. Garcia-Jares, I. Rodriguez,
M. Gomez, and T. Ternes. 2004. Behaviour
of pharmaceuticals, cosmetics and hormones
in a sewage treatment plant. Water Res. 38:
2918–2926.
Carcavallo, R. U. 1999. Climatic factors related
to Chagas disease transmission. Mem. Inst
Oswaldo Cruz 94: 367–369.
314 C. H. REDSHAW ET AL.
Casteel, M. J., M. D. Sobsey, and J. P. Mueller.
2006. Fecal contamination of agricultural
soils before and after hurricane-associated
flooding in North Carolina. J. Environ. Sci.
Health A 41: 173–184.
Centers for Disease Control and Prevention.
2006. Mold prevention strategies and
possible health effects in the aftermath of
hurricanes and major floods.Morbid. Mortal.
Weekly Rep. 55(RR8, suppl. S): 1–27.
Centers for Disease Control and Prevention.
2010a. Emergence of Cryptococcus gattii:
Pacific Northwest, 2004–2010. Morbid.
Mortal. Weekly Rep. 59: 865–868.
Centers for Disease Control and Prevention.
2010b. Locally acquired dengue—Key West,
Florida, 2009–2010. Morbid. Mortal. Weekly
Rep. 59: 577–581.
Chae, E.-H., W. K. Tong, S.-J. Rhee, and T. D.
Henderson. 2005. The impact of flooding
on the mental health of affected people in
South Korea. Commun. Mental Health J. 41:
633–645.
Checkley, W., L. D. Epstein, R. H. Gilman,
D. Figueroa, R. I. Cama, J. A. Patz, and
R. E. Black. 2000. Effects of EI Niño and
ambient temperature on hospital admissions
for diarrhoeal diseases in Peruvian children.
Lancet 355: 442–450.
Chen, L., K. Verrall, and S. Tong. 2006. Air
particulate pollution due to bushfires and
respiratory hospital admissions in Brisbane,
Australia. Int. J. Environ. Health Res. 16:
181–191.
Chitsulo, L., D. Engels, A. Montresor, and
L. Savioli. 2000. The global status of
schistosomiasis and its control. Acta Trop.
77: 41–51.
Cochrane, K. L., C. De Young, D. Soto, and
T. Bahri. 2009. Climate change implications
for fisheries and aquaculture: Overview of
current scientific knowledge. Rome, Italy:
Food and Agriculture Organization of the
United Nations.
Colwell, R. R. 1996. Global climate and infec-
tious disease: The cholera paradigm. Science
274: 2025–2031.
Colwell, R. R., and A. Huq. 1998. Global
microbial ecology: Biogeography and
diversity of Vibrios as a model. J. Appl.
Microbiol. 85: 134S–137S.
Conlon, K. C., N. B. Rajkovich, J. L. White-
Newsome, L. Larsen, and M. S. O’Neill.
2011. Preventing cold-related morbidity and
mortality in a changing climate. Maturitas
69: 197–202.
Cooney, C. M. 2011. Climate change and
infectious disease: Is the future here?
Environ. Health Perspect. 119: A394–A397.
Costello, A., M. Maslin, H. Montgomery, A. M.
Johnson, and P. Ekins. 2011. Global health
and climate change: moving from denial
and catastrophic fatalism to positive action.
Philos. Trans. R. Soc. A 369: 1866–1882.
D’Ippoliti, D., P. Michelozzi, C. Marino, F.
de’Donato, B. Menne, K. Katsouyanni, U.
Kirchmayer, A. Analitis, M. Medina-Ramon,
A. Paldy, R. Atkinson, S. Kovats, L. Bisanti,
A. Schneider, A. Lefranc, C. Iniguez, and
C. Perucci. 2010. The impact of heat waves
on mortality in 9 European cities: Results
from the EuroHEAT project. Environ. Health
9: 37.
Datta, K., K. H. Bartlett, R. Baer, E. Byrnes,
E. Galanis, J. Heitman, L. Hoang, M. J.
Leslie, L. MacDougall, S. S. Magill, M. G.
Morshed, and K. A. Marr. 2009. Spread of
Cryptococcus gattii into Pacific Northwest
region of the United States. Emerg. Infect.
Dis. 15: 1185–1191.
Daughton, C. G., and T. A. Ternes. 1999.
Pharmaceuticals and personal care prod-
ucts in the environment: Agents of subtle
change? Environ. Health Perspect. 107:
907–938.
Depledge, M. 2011a. Does the pharmaceutical
industry need a new prescription? Sci.
Parliment 68: 44–45.
Depledge, M. 2011b. Reduce drug waste in
the environment. Nature 478: 36.
Diaz, J. H. 2004. The public health impact of
hurricanes and major flooding. J. Louisiana
State Med. Soc. 156: 145–150.
Diniz, S. A., F. L. Silva, A. V. C. Neta, R. Bueno, R.
M. S. N. C. Guerra, A. L. Abreu-Silva, and R.
L. Santos. 2008. Animal reservoirs for visceral
leishmaniasis in densely populated urban
areas. J. Infect. Dev. Countries 2: 24–33.
PHARMACEUTICAL USE AND CLIMATE CHANGE 315
Dixit, A., S. F. Carroll, and S. T. Qureshi. 2009.
Cryptococcus gattii: An emerging cause of
fungal disease in North America. Interdiscip.
Perspect. Infect. Dis. 2009: 840452.
Du, W., G. J. FitzGerald, M. Clark, and X.-
Y. Hou. 2010. Health impacts of floods.
Prehosp. Disaster Med. 25:265–272.
Editorial. 2009. A commission on climate
change. Lancet 373: 1659.
Eisen, R. J., G. E. Glass, L. Eisen, J. Cheek, R. E.
Enscore, P. Ettestad, and K. L. Gage. 2007.
A spatial model of shared risk for plague
and hantavirus pulmonary syndrome in the
southwestern United States. Am. J. Trop.
Med. Hyg. 77: 999–1004.
El Adlouni, S., C. Beaulieu, T. B. M. J. Ouarda,
P. L. Gosselin, and A. Saint-Hilaire. 2007.
Effects of climate on West Nile virus
transmission risk used for public health
decision-making in Quebec. Int. J. Health
Geogr. 6: 1–7.
Enscore, R. E., B. J. Biggerstaff, T. L. Brown, R.
E. Fulgham, P. J. Reynolds, D. M. Engelthaler,
C.E. Levy, R. R. Parmenter, J. A. Montenieri,
J. E. Cheek, R. K. Grinnell, P. J. Ettestad, and
K. L. Gage. 2002. Modeling relationships
between climate and the frequency of
human plague cases in the southwestern
United States, 1960–1997. Am. J. Trop. Med.
Hyg. 66: 186–196.
Epstein, P. R. 2001a. Climate change and
emerging infectious diseases. Microbes
Infect. 3: 747–754.
Epstein, P. R. 2001b. West Nile virus and the
climate. J. Urban Health 78: 367–371.
Fischer, D., S. M. Thomas, F. Niemitz, B.
Reineking, and C. Beierkuhnlein. 2011.
Projection of climatic suitability for Aedes
albopictus Skuse (Culicidae) in Europe under
climate change conditions. Global Planet
Change 78: 54–64.
Fleming, L. E., B. Kirkpatrick, L. C. Backer, C.
J. Walsh, K. Nierenberg, J. Clark, A. Reich,
J. Hollenbeck, J. Benson, and Y. S. Cheng.
2011. Review of Florida red tide and human
health effects. Harmful Algae 10: 224–233.
Franke, C. R., M. Ziller, C. Staubach, and M.
Latiff. 2002. Impact of the El Niño/southern
oscillation on visceral leishmaniasis, Brazil.
Emerg. Infect. Dis. 8:n914–917.
Friel, S., K. Bowen, D. Campbell-Lendrum,
H. Frumkin, A. J. McMichael, and K.
Rasanathan. 2011. Climate change,
noncommunicable diseases, and devel-
opment: The relationships and common
policy opportunities. Annu. Rev. Public
Health 32: 133.
Gage, K.L., T.R. Burkot, R.J. Eisen, and E.B.
Hayes. 2008. Climate and vectorborne
diseases. Am. J. Prev. Med. 35: 436–450.
Gajadhar, A. A., and J. R. Allen. 2004. Factors
contributing to the public health and eco-
nomic importance of waterborne zoonotic
parasites. Vet. Parasitol. 126: 3–14.
Galanis, E., and L. MacDougall. 2010.
Epidemiology of Cryptococcus gattii, British
Columbia, Canada, 1999–2007. Emerg.
Infect. Dis. 16: 251–257.
Gilbert, N. 2011. Drug waste harms fish.
Nature 476: 265.
Gjenero-Margan, I., B. Aleraj, D. Krajcar, V.
Lesnikar, A. Klobucˇar, I. Pem-Novosel, S.
Kurecˇic´-Filipovic´, S. Komparak, R. Martic´,
S. Duricˇic´, L. Betica-Radic´, J. Okmadžic´, T.
Vilibic´-Cˇavlek, A. Babic´-Erceg, B. Turkovic´, T.
Avsic´-Županc, I. Radic´, M. Ljubic´, K. Sarac,
N. Benic´, and G. Mlinaric´-Galinovic´. 2011.
Autochthonous dengue fever in Croatia,
August–September 2010. Eurosurveillance
16: 19805.
Golet, E. M., A. Strehler, A. C. Alder, and
W. Giger. 2002. Determination of fluoro-
quinolone antibacterial agents in sewage
sludge and sludge-treated soil using accel-
erated solvent extraction followed by
solid-phase extraction. Anal. Chem. 74:
5455–5462.
Gratz, N. G. 2004. Critical review of the
vector status of Aedes albopictus. Med. Vet.
Entomol. 18: 215–227.
Gryseels, B., K. Polman, J. Clerinx, and L.
Kestens. 2006. Human schistosomiasis.
Lancet 368: 1106–1118.
Gubler, D. J., P. Reiter, K. L. Ebi, W. Yap,
R. Nasci, and J. A. Patz. 2001. Climate
variability and change in the United States:
316 C. H. REDSHAW ET AL.
Potential impacts on vector and rodent-
borne diseases. Environ. Health Perspect.
109: 223–233.
Haines, A., and J. A. Patz. 2004. Health effects
of climate change. J. Am. Med. Assoc. 291:
99–103.
Halling-Sorensen, B., S. N. Nielsen, P. F. Lanzky,
F. Ingerslev, H. C. H. Lutzhoft, and S. E.
Jorgensen. 1998. Occurrence, fate and
effects of pharmaceutical substances in the
environment—A review. Chemosphere 36:
357–394.
Harvell, C. D., K. Kim, J. M. Burkholder, R.
R. Colwell, P. R. Epstein, D. J. Grimes, E. E.
Hofmann, E. K. Lipp, A. D. M. E. Osterhaus,
R. M. Overstreet, J. W. Porter, G. W. Smith,
and G. R. Vasta. 1999. Emerging marine
diseases—Climate links and anthropogenic
factors. Science 285: 1505–1510.
Harvell, C. D., C. E. Mitchell, J. R. Ward, S.
Altizer, A. P. Dobson, R. S. Ostfeld, and
M. D. Samuel. 2002. Climate warming and
disease risks for terrestrial and marine biota.
Science 296: 2158–2162.
Hay, S. I., D. J. Rogers, S. E. Randolph, D. I.
Stern, J. Cox, G. D. Shanks, and R. W. Snow.
2002. Hot topic or hot air? Climate change
and malaria resurgence in East African
highlands. Trends Parasitol. 18: 530–534.
Heberer, T. 2002. Occurrence, fate, and
removal of pharmaceutical residues in the
aquatic environment: A review of recent
research data. Toxicol. Lett. 131: 5–17.
Heberer, T., B. Fuhrmann, K. Schmidt-Baumler,
D. Tsipi, V. Koutsouba, and A. Hiskia. 2001.
Occurrence of pharmaceutical residues
in sewage, river, ground, and drinking
water in Greece and Berlin (Germany). In
Pharmaceuticals and personal care products
in the environment: Scientific and regulatory
issues. ACS symposium series 791, ed.
G. Daughton and T. Jones-Lepp, 70–83.
Washington, DC: American Chemical
Society.
Hirsch, R., T. A. Ternes, K. Haberer, and K.-L.
Kratz. 1999. Occurrence of antibiotics in the
aquatic environment. Sci. Total Environ. 225:
109–118.
Hlady, W. G., and K. C. Klontz. 1996. The
epidemiology of Vibrio infections in Florida,
1981–1993. J. Infect. Dis. 173: 1176–1183.
Hofmann, E., S. Ford, E. Powell, and J. Klinck.
2001. Modeling studies of the effect of
climate variability on MSX disease in eastern
oyster (Crassostrea virginica) populations.
Hydrobiologia 460: 195–212.
Intergovernmental Panel on Climate Change.
2007. Climate change 2007: The Physical
science basis. Contribution of Working
Group I to the Fourth assessment report
of the Intergovernmental Panel on Climate
Change, ed. S. Solomon, D. Qin, M.
Manning, Z. Chen, M. Marquis, K. B. Averyt,
M. Tignor, and H. L. Miller. http://www.
ipcc.ch/publications_and_data/ar4/wg1/en/
contents.html
Intergovernmental Panel on Climate Change.
2012. Managing the risks of extreme events
and disasters to advance climate change
adaptation. A special report of Working
Groups I and II of the Intergovernmental
Panel on Climate Change, ed. C. B. Field, V.
Barros, T. F. Stocker, D. Qin, D. J. Dokken,
K. L. Ebi, M. D. Mastrandrea, K. J. Mach,
G.-K. Plattner, S. K. Allen, M. Tignor and
P. M. Midgley. New York, NY: Cambridge
University Press.
Kang, J. X. 2011. Omega-3: A link between
global climate change and human health.
Biotechnol. Adv. 29:388–390.
Kinney, P. L. 2008. Climate change, air quality,
and human health. Am. J. Prev. Med. 35:
459–467.
Kümmerer, K. 2010. Pharmaceuticals in the
environment. Annu. Rev. Environ. Resources
35: 57–75.
Kümmerer, K. 2009a. Antibiotics in the
aquatic environment—A review—Part I.
Chemosphere 75: 417–434.
Kümmerer, K. 2009b. Antibiotics in the
aquatic environment—A review—Part II.
Chemosphere 75: 435–441.
Kundzewicz, Z. W., L. J. Mata, N. W. Arnell, P.
Döll, B. Jimenez, K. Miller, T. Oki, Z. S¸en,
and I. Shiklomanov. 2008. The implications
of projected climate change for freshwater
PHARMACEUTICAL USE AND CLIMATE CHANGE 317
resources and their management. Hydrol.
Sci. J. 53: 3–10.
Kundzewicz, Z. W., M. Radziejewski, and I.
Pinskwar. 2006. Precipitation extremes in
the changing climate of Europe. Climate Res.
31: 51.
Kunii, O., S. Nakamura, R. Abdur, and S.
Wakai. 2002. The impact on health and risk
factors of the diarrhoea epidemics in the
1998 Bangladesh floods. Public Health 116:
68–74.
La Ruche, G., Y. Souarès, A. Armengaud, F.
Peloux-Petiot, P. Delaunay, P. Desprès, A.
Lenglet, F. Jourdain, I. Leparc-Goffart, F.
Charlet, L. Ollier, K. Mantey, T. Mollet,
J.P. Fournier, R. Torrents, K. Leitmeyer, P.
Hilairet, H. Zeller, W. Van Bortel, D. Dejour-
Salamanca, M. Grandadam, andM. Gastellu-
Etchegorry. 2010. First two autochthonous
dengue virus infections in metropolitan
France. Eurosurveillance 15: 19676.
Lafferty, K. D. 2009. The ecology of climate
change and infectious diseases. Ecology 90:
888–900.
Leirs, H., R. Verhagen, W Verheyen, P.
Mwanjabe, and T. Mbise. 1996. Forecasting
rodent outbreaks in Africa: An ecological
basis for Mastomys control in Tanzania. J.
Appl. Ecol. 33: 937–943.
Lima, M., P. A. Marquet, and F. M. laksic. 1999.
El Niño events, precipitation patterns, and
rodent outbreaks are statistically associated
in semiarid Chile. Ecography 22: 213–218.
Lindgren, E., L. Tälleklint, and T. Polfeldt. 1999.
Impact of climatic change on the north-
ern latitude limit and population density
of the disease-transmitting European tick
Ixodes ricinus. Environ. Health Perspect. 108:
119–123.
Lipp, E., R. Kurz, R. Vincent, C. Rodriguez-
Palacios, S. Farrah, and J. Rose. 2001a. The
effects of seasonal variability and weather
on microbial fecal pollution and enteric
pathogens in a subtropical estuary. Estuaries
Coasts 24: 266–276.
Lipp, E., N. Schmidt, M. Luther, and J. Rose.
2001b. Determing the effects of El Niño-
Southern Oscillation events on coastal water
quality. Estuaries Coasts 24: 491–497.
Lipp, E. K., A. Huq, and R. R. Colwell. 2002.
Effects of global climate on infectious dis-
ease: The cholera model. Clin. Microbiol.
Rev. 15: 757–770.
Lipp, E. K., and H. Rose. 1997. The role of
seafood in foodborne diseases in the United
States of America. Rev. Sci. Technol. Off. Int.
Epiz. 16: 620–640.
Lobitz, B., L. Beck, A. Huq, B. Wood, G.
Fuchs, A. S. G. Faruque, and R. Colwell.
2000. Climate and infectious disease: Use
of remote sensing for detection of Vibrio
cholerae by indirect measurement. Proc.
Natl. Acad. Sci. USA 97: 1438–1443.
López, O., A. F. Hernández, L. Rodrigo, F.
Gil, G. Pena, J. L. Serrano, T. Parrón, E.
Villanueva, and A. Pla. 2007. Changes
in antioxidant enzymes in humans with
long-term exposure to pesticides. Toxicol.
Lett. 171: 146–153.
Lugeri, N., Z. Kundzewicz, E. Genovese, S.
Hochrainer, and M. Radziejewski. 2010.
River flood risk and adaptation in Europe—
Assessment of the present status. Mitig.
Adapt. Strat. Global Change 15: 621–639.
MacDougall, L., S. E. Kidd, E. Galanis, S. Mak,
M. J. Leslie, P. R. Cieslak, J. W. Kronstad,
M. G. Morshed, and K. H. Bartlett. 2007.
Spread of Cryptococcus gattii in British
Columbia, Canada, and detection in the
Pacific Northwest, USA. Emerg. Infect. Dis.
13: 42–50.
Majoros, G., Z. Fehér, T. Deli, and G. Földvári.
2008. Establishment of Biomphalaria
tenagophila snails in Europe. Emerg. Infect.
Dis. 14: 1812–1814.
Martens, W. J. M., T. H. Jetten, and D. A. Focks.
1997. Sensitivty of malaria, schistosomiasis
and dengue to global warming. Climatic
Change 35: 145–156.
Mas-Coma, S., M. A. Valero, and M. D.
Bargues. 2009. Climate change effects on
trematodiases, with emphasis on zoonotic
fascioliasis and schistosomiasis. Vet. Parasitol.
163: 264–280.
McMichael, A. J., R. E. Woodruff, and S.
Hales. 2006. Climate change and human
health: Present and future risks. Lancet 367:
859–869.
318 C. H. REDSHAW ET AL.
Mills, J. N., K. L. Gage, and A. S. Khan. 2010.
Potential influence of climate change on
vector-borne and zoonotic diseases: A
review and proposed research plan. Environ.
Health Perspect. 118: 1507–1514.
Mitchell, C. J., B. R. Miller, and D. J. Gubler.
1987.Vector competenceofAedes albopictus
from Houston, Texas, for dengue serotypes
1 to 4, yellow fever and Ross River viruses. J.
Am. Mosq. Control. Assoc. 3: 460–465.
Morgan, J. A. T., R. J. Dejong, S. D. Snyder, G.
M. Mkoji, and E. S. Loker. 2001. Schistosoma
mansoni and Biomphalaria: Past history and
future trends. Parasitology 123: 211–228.
Nakazawa, Y., R. Williams, A. T. Peterson, P.
Mead, E. Staples, and K. L. Gage. 2007.
Climate change effects on plague and
tularemia in the United States. Vector Borne
Zoonotic Dis. 7: 529–540.
O’Shea, M. L., and R. Field. 1992. Detection
and disinfection of pathogens in storm-
generated flows. Can. J. Microbiol. 38:
267–276.
Occhipinti-Ambrogi, A. 2007. Global change
and marine communities: Alien species
and climate change. Mar. Pollut. Bull. 55:
342–352.
Olesen, J. E., M. Trnka, K. C. Kersebaum, A.
O. Skjelvåg, B. Seguin, P. Peltonen-Sainio, F.
Rossi, J. Kozyra, and F. Micale. 2011. Impacts
and adaptation of European crop production
systems to climate change. Eur. J. Agron. 34:
96–112.
Otranto, D., and R. Wall. 2008. New strategies
for the control of arthropod vectors of
disease in dogs and cats. Med. Vet. Entomol.
22: 291–302.
Parmenter, R. R., E. P. Yadav, C. A. Parmenter,
P. Ettestad, and K. L. Gage. 1999. Incidence
of plague associated with increased winter-
spring precipitation in New Mexico. Am. J.
Trop. Med. Hyg. 61: 814–821.
Pascual, M., X. Rodó, S.P. Ellner, R. Colwell,
and M. J. Bouma. 2000. Cholera dynamics
and El Niño-Southern oscillation. Science
289: 1766–1769.
Pearce, E. J., and A. S. MacDonald. 2002. The
immunobiology of schistosomiasis. Nature
Rev. 2: 499–511.
Perfect, J. R., W. E. Dismukes, F. Dromer, D.L.
Goldman, J. R. Graybill, R. J. Hamill, T. S.
Harrison, R. A. Larsen, O. Lortholary, M.-H.
Nguyen, P. G. Pappas, W. G. Powderly, N.
Singh, J. D. Sobel, and T. C. Sorrell. 2010.
Clinical practice guidelines for the manage-
ment of cryptococcal disease: 2010 Update
by the Infectious Diseases Society of
America. Clin. Infect. Dis. 50: 291–322.
Peterson, A. T., V. Sanchez-Cordero, C. B.
Beard, and J. M. Ramsey. 2002. Ecological
niche modeling and potential reservoirs for
Chagas disease, Mexico. Emerg. Infect. Dis.
8: 662.
Pianetti, A., L. Sabatini, F. Bruscolini, F.
Chiaverini, and G. Cecchetti. 2004. Faecal
contamination indicators, Salmonella, Vibrio
and Aeromonas in water used for the irri-
gation of agricultural products. Epidemiol.
Infect. 132: 231–238.
Pointier, J. P., P. David, and P. Jarne. 2005.
Biological invasions: The case of planorbid
snails. J. Helminthol. 79: 249–256.
Portier, C. J., T. K. Thigpen, S. R. Carter, C.
H. Dilworth, A. E. Grambsch, J. Gohlke,
J. Hess, S. N. Howard, G. Luber, J. T.
Lutz, T. Maslak, N. Prudent, M. Radtke, J.
P. Rosenthal, T. Rowles, P. A. Sandifer, J.
Scheraga, P. J. Schramm, D. Strickman, J.
M. Trtanj, and P.-Y. Whung. 2010. A human
health perspective on climate change: A
report outlining the research needs on the
human health effects of climate change.
Research Triangle Park, NC: Environmental
Health Perspectives/National Institute of
Environmental Health Sciences.
Queyriaux, B., A. Armengaud, C. Jeannin,
E. Couturier, and F. Peloux-Petiot. 2008.
Chikungunya in Europe. Lancet 371:
723–724.
Rahel, F. J., and J. D. Olden. 2008. Assessing the
effects of climate change on aquatic inva-
sive species (Evaluación de los efectos del
cambio climático sobre especies acuáticas
invasoras). Conserv. Biol. 22: 521–533.
Rappole, J. H., S. R. Derrickson, and Z.
Hubálek. 2000. Migratory birds and
spread of West Nile virus in the Western
Hemisphere. Emerg. Infect. Dis. 6: 319–328.
PHARMACEUTICAL USE AND CLIMATE CHANGE 319
Reacher, M., K. McKenzie, C. Lane, T. Nichols,
I. Kedge, A. Iversen, P. Hepple, T. Walter, C.
Laxton, J. Simpson, and Lewes Flood Action
Recovery Team. 2004. Health impacts of
flooding in Lewes: A comparison of reported
gastrointestinal and other illness and men-
tal health in flooded and non-flooded
households. Commun. Dis. Public Health 7:
56–63.
Ready, P. D. 2010. Leishmaniasis emergence in
Europe. Eurosurveillance 15: 19505.
Reidsma, P., F. Ewert, and A. O. Lansink. 2007.
Analysis of farm performance in Europe
under different climatic and management
conditions to improve understanding of
adaptive capacity. Climatic Change 84:
403–422.
Reif, J. S., L. Wimmer, J. A. Smith, D. A.
Dargatz, and J. M. Cheney. 1989. Human
cryptosporidiosis associated with an epi-
zootic in calves. Am. J. Public Health 79:
1528–1530.
Relman, D. A., M. A. Hamburg, E. R. Choffnes,
and A. Mack. 2008. Global climate change
and extreme weather events: Understanding
the contributions to infectious disease
emergence: Workshop summary. Institute
of Medicine Forum on Microbial Threats.
Washington, DC: National Academies
Press.
Rezza, G., L. Nicoletti, R. Angelini, R. Romi,
A. C. Finarelli, M. Panning, P. Cordioli, C.
Fortuna, S. Boros, F. Magurano, G. Silvi, P.
Angelini, M. Dottori, M. G. Ciufolini, G. C.
Majori, and A. Cassone. 2007. Infection with
Chikungunya virus in Italy: An outbreak in a
temperate region. Lancet 370: 1840–1846.
Riggs, M. A., C. Y. Rao, C. M. Brown, D. Van
Sickle, K. J. Cummings, K. H. Dunn, J. A.
Deddens, J. Ferdinands, D. Callahan, R.
L. Moolenaar, and L. E. Pinkerton. 2008.
Resident cleanup activities, characteristics
of flood-damaged homes and airborne
microbial concentrations in New Orleans,
Louisiana, October 2005. Environ. Res. 106:
401–409.
Rohr, J. R., T. R. Raffel, J. M. Romansic,
H. McCallum, and P. J. Hudson. 2008.
Evaluating the links between climate, disease
spread, and amphibian declines. Proc. Natl.
Acad. Sci. USA 105: 17436–17441.
Rose, J. B., P. R. Epstein, E. K. Lipp, B. H.
Sherman, S. M. Bernard, and J. A. Patz.
2001. Climate variability and change in
the United States: Potential impacts on
water- and foodborne diseases caused by
microbiological agents. Environ. Health
Perspect. 109: 211–222.
Rose, J. B., D. E. Huffman, and A. Gennaccaro.
2002. Risk and control of waterborne
cryptosporidiosis. FEMS Microbiol. Rev. 26:
113–123.
Rosenthal, E., P. Marty, I. Poizot-Martin,
J. Reynes, F. Pratlong, A. Lafeuillade,
D. Jaubert, O. Boulat, J. Dereure, F.
Gambarelli, J.-A. Gastaut, P. Dujardin,
P. Dellamonica, and J.-P. Cassuto. 1995.
Visceral leishmaniasis and HIV-1 co-
infection in southern France. R. Soc. Trop.
Med. Health 89: 159–162.
Royal Society. 2008. Ground-level ozone in
the 21st century: Future trends, impacts
and policy implications. Royal Society Policy
Document 15/08. London, UK.
Schmidt-Chanasit, J., M. Haditsch, S. Günter,
K. Stark, and C. Frank. 2010. Dengue
virus infection in a traveller returning from
Croatia to Germany. Eurosurveillance 15:
19667.
Sorrell, T. C. 2001. Cryptococcus neoformans
variety gattii. Med. Mycol. 39: 155–168.
Speldewinde, P. C., A. Cook, P. Davies, and
P. Weinstein. 2009. A relationship between
environmental degradation and mental
health in rural Western Australia. Health
Place 15: 880–887.
Stapp, P., M. F. Antolin, and M. Ball. 2004.
Patterns of extinction in prairie dog
metapopulations: Plague outbreaks follow El
Nino events. Front Ecol. Environ. 2: 235–240.
Stern, N. H. 2006. Stern review: The economics
of climate change, Vol. 30: London, UK: HM
Treasury.
Stillerman, K. P., D. R. Mattison, L. C. Giudice,
and T. J. Woodruff. 2008. Environmental
exposures and adverse pregnancy outcomes:
A review of the science. Reprod. Sci. 15:
631–650.
320 C. H. REDSHAW ET AL.
Taggart, M. A., K. R. Senacha, R. E. Green,
Y. V. Jhala, B. Raghavan, A. R. Rahmani,
R. Cuthbert, D. J. Pain, and A. A. Meharg.
2007. Diclofenac residues in carcasses of
domestic ungulates available to vultures in
India. Environ. Int. 33: 759–765.
Tanabe, K., S. Nakamura, and O. Kunii.
1999. Bacteriological survey of diarrhoea
epidemics in the 1998 Bangladesh floods.
Kansenshogaku Zasshi 73: 91–922.
Taylor, N. G. H., D. W. Verner-Jeffreys,
and C. Baker-Austin. 2011. Aquatic sys-
tems: Maintaining, mixing and mobilising
antimicrobial resistance? Trends Ecol.
Evolution 26: 278–284.
Ternes, T. A. 1998. Occurrence of drugs in
German sewage treatment plants and rivers.
Water Res. 32: 3245–3260.
Trnka, M., F. Muška, D. Semerádová, M.
Dubrovský, E. Kocmánková, and Z. Žalud.
2007. European corn borer life stage model:
Regional estimates of pest development
and spatial distribution under present
and future climate. Ecol. Model. 207:
61–84.
United Nations Environmental Programme.
2009. Climate change science compendium,




United Nations Environmental Programme
and Artic Monitoring and Assessment
Programme. 2010. Climate Change and
POPs: Predicting the impact. Report of the
United Nations Environmental Programme/
Artic Monitoring and Assessment Programme
Expert Group: Secretariats of the Stockholm
Convention in Geneva, Switzerland, and
the Arctic Monitoring and Assessment
Programme, Oslo, Norway.
U.S. Environmental Protection Agency Office of
Air and Radiation. 1989. Report to Congress
on indoor air quality, Vol. II: Assessment
and control of indoor air pollution. http://
nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=
9100LMBU.txt
Vázquez, A., M. A. Jiménez-Clavero, L. Franco,
O. Donoso-Mantke, V. Sambri, M. Niedrig,
H. Zeller, and A. Tenorio. 2011. Usutu
virus—Potential risk of human disease in
Europe. Eurosurveillance 16: 19935.
Verger, P., M. Rotily, C. Hunault, J. Brenot, E.
Baruffol, and D. Bard. 2003. Assessment of
exposure to a flood disaster in a mental-
health study. J. Expos. Anal. Environ.
Epidemiol. 13: 436–442.
Wittman, R. J., and G. J. Flick. 1995. Microbial
contamination of shellfish: Prevalence, risk
to human health, and control strategies.
Annu. Rev. Public Health 16: 123–140.
World Health Organization. 2011a. Water-
related diseases. Scabies. World Health
Organization. http://www.who.int/water_
sanitation_health/diseases/scabies/en/
(accessed September 9, 2011).
World Health Organization. 2011b. Water-
related DIseases. Trachoma. World Health
Organization 2001. http://www.who.int/
water_sanitation_health/diseases/trachoma/
en/ (accessed September 9, 2011).
World Health Organization. 2009. Protecting
health from climate change: Connecting
science, policy and people. http://www.
who.int/globalchange/publications/reports/
9789241598880/en/index.html
World Health Organization. 2010. World
malaria report 2010. Geneva, Switzerland:
World Health Organization.
Wright, G. D. 2010. Antibiotic resistance in the
environment: A link to the clinic? Curr. Opin.
Microbiol. 13: 589–594.
Zhou, X.-N., G.-J. Yang, K. Yang, X.-H. Wang,
Q.-B. Hong, L.-P. Sun, J. B. Malone, T. K.
Kristensen, N. R. Bergquist, and J. Utzinger.
2008. Potential impact of climate change on
schistosomiasis transmission in China. Am. J.
Trop. Med. Hyg. 78: 188–194.
